Evaxion Biotech Stock (NASDAQ:EVAX)
Previous Close
$4.37
52W Range
$2.38 - $27.50
50D Avg
$5.63
200D Avg
$13.32
Market Cap
$198.86K
Avg Vol (3M)
$1.16M
Beta
-0.23
Div Yield
-
EVAX Company Profile
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
EVAX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| RVMD | Revolution Medicines, Inc. |
| RNAZ | TransCode Therapeutics, Inc. |
| BDRX | Biodexa Pharmaceuticals Plc |
| ZVSA | ZyVersa Therapeutics, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| PHIO | Phio Pharmaceuticals Corp. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| ALLR | Allarity Therapeutics, Inc. |
| VRAX | Virax Biolabs Group Limited |
| REVB | Revelation Biosciences, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| UNCY | Unicycive Therapeutics, Inc. |
| ZURA | Zura Bio Limited |